The Assessment of Ventricular Arrhythmia Indicators Based on Electrocardiography in Patients With Differentiated Thyroid Cancer Followed Up With Levothyroxine Suppression

Angiology. 2021 Aug;72(7):657-663. doi: 10.1177/0003319721993343. Epub 2021 Feb 9.

Abstract

Levothyroxine suppression therapy (LST) can cause some unfavorable effects on the cardiovascular system in patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate ventricular arrhythmia predictors based on electrocardiography (ECG) in patients with DTC with LST. The ECG parameters including QT, corrected QT (QTc), Tp-e intervals, Tp-e/QT, and Tp-e/QTC ratios of 265 patients with DTC who met the inclusion criteria were compared with 100 controls. No difference was observed in the number of patients with DTC and controls with prolonged and borderline QTc interval (P = .273). Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios were significantly higher in patients (P = .002, P = .02, P = .003; respectively). Linear regression analysis suggested that male gender was a predictor of higher Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios (β = 4.322, R2 = 0.024, P = .042; β = 0.016, R2 = 0.048, P = .005; β = 0.015, R2 = 0.044, P = .006, respectively). A higher serum fT4 level was found to be associated with a higher Tp-e/QT ratio (β = 0.018, R2 = 0.089, P = .007). Ventricular arrhythmia indicators were found to be higher in patients with DTC with LST. Defining ventricular arrhythmia predictors through ECG, an easily accessible cardiac diagnostic tool, can be potentially useful in raising awareness of the possible cardiac harm of LST.

Keywords: electrocardiography; levothyroxine suppression; thyroid cancer; ventricular arrhythmia.

MeSH terms

  • Adult
  • Arrhythmias, Cardiac / diagnosis*
  • Arrhythmias, Cardiac / epidemiology*
  • Case-Control Studies
  • Cross-Sectional Studies
  • Electrocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Thyroid Neoplasms / complications*
  • Thyroid Neoplasms / drug therapy
  • Thyroid Neoplasms / surgery
  • Thyroidectomy
  • Thyroxine / therapeutic use

Substances

  • Thyroxine